Minimizing Particulate Contamination in Single-Use Systems

Recorded webinar

Every source of contamination must be considered in biomanufacturing processes, drug formulation, and drug delivery. Potential sources of contamination are single-use systems (SUS) and components. Learn more about potential contamination risks and how to monitor and mitigate them.

In this webinar, Mark Bumiller and Joy Xiaohui Chen discuss particulate contamination as an important consideration in pharmaceutical production, and even more so in bioprocess production and delivery as well as in ophthalmic applications.

Key topics include:

  • Staying ahead of emerging standards
  • Technical and regulatory concerns
  • Clean manufacturing environments
  • Continuous testing 

 

About the Presenter 

Mark Bumiller
Scientific Instruments Technology Manager, Entegris

mark-bumiller-11457-90x90

Mark has worked in the field of particle size analysis for over 35 years. Positions held include product manager at Hiac Royco (5 years), technical support manager and vice president of business development at Malvern Instruments (17 years), vice president of particle products at Horiba (6 years) and technology manager at Particle Sizing Systems, LLC, and now Entegris (6 years). He has served as a member of the expert committee for USP <788>, the executive committee of the International Fine Particle Research Institute (IFPRI), and the executive committee of Particle Technology Forum of the American Institute of Chemical Engineers. Mark is an active member of Technical Committee 24 within ISO helping to write standards for particle size and zeta potential analysis. His B.S. in chemical engineering was earned at Carnegie Mellon University in Pittsburgh, PA.

Joy Xiaohui Chen
Senior Application Engineer, Life Sciences, Entegris

JoyChen3

 Joy Xiaohui Chen has more than a decade of industrial experience, with expertise in developing single-use bioprocessing solutions including bioprocessing bags, membrane filters, bioreactors for different pharmaceutical applications. She has previously worked at GE Life Sciences (now Cytiva) and GE Global Research in the areas of physiological monitoring, disease diagnostics and prognostics, cell and gene therapy and precision medicine.